We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intercure Ltd | TSX:INCR.U | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.53 | 1.47 | 1.64 | 0 | 01:00:00 |
Fourth Quarter 2021 Key Financial & Operating Highlights
Full Year 2021 Key Financial & Operating Highlights
Post-fourth quarter 2021 Highlights
“Our fourth quarter results came in stronger than we initially expected as we successfully continue to expand InterCure's branded product portfolio, scale up our unique global supply chain and expand our pharmaceutical grade medical cannabis dispensing operation,” said InterCure CEO Alexander Rabinovitch, adding “Our results throughout 2021 reflect the outstanding work we've accomplished and our focus on executing our profitable growth strategy. As regulations are evolving favorably, there is huge potential in all of our operating territories, and we are well positioned for the growth ahead. We will continue focusing on executing our profitable growth strategy, creating value for our stakeholders."
Key Q4 and Full Year 2021 Financial Highlights – Cannabis Sector
(In thousands $)
Full Year | 2020 | 2021(Preliminary) | 2021 |
Revenues | 26,628 | 87,000 | 88,779 |
Gross Profit(1) | 12,441 | 37,799 | |
Adjusted EBITDA(2) | 6,508 | 22,566 |
Fourth Quarter | Q4-20 | Q4-21(Preliminary) | 2021 |
Revenues | 11,093 | 31,000 | 32,632 |
Gross Profit(1) | 5,446 | 14,990 | |
Adjusted EBITDA(2) | 3,549 | 8,635 |
Q2-20 | Q3-20 | Q4-20 | Q1-21 | Q2-21 | Q3-21 | Q4-21 | ||||||||
Revenues | 4,580 | 9,211 | 11,093 | 13,532 | 18,518 | 25,260 | 32,632 | |||||||
Gross Profit(1) | 1,971 | 4,403 | 5,446 | 6,316 | 7,889 | 10,106 | 14,990 | |||||||
GP Margin | 43% | 48% | 49% | 47% | 43% | 40% | 46% | |||||||
Adjusted EBITDA(2) | 644 | 2,852 | 3,549 | 4,121 | 4,791 | 5,749 | 8,635 | |||||||
Adjusted EBITDA(2) Margin | 14% | 31% | 32% | 30% | 26% | 23% | 26% |
(1) Gross profit before effect of fair value.(2) EBITDA adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses (or income). This is a non-IFRS financial measure and does not have a standardized meaning prescribed by IFRS, please see “Non-IFRS Measures” below.
Rescheduled Webcast and Conference CallManagement will conduct a webcast on Wednesday, April 6, 2022 at 5:30 p.m. (Eastern Time) to review the results as well as provide an overview of the Company’s recent milestones and growth strategy.
To access the conference call, United States participants please dial (844) 310-5056, or for international callers, 1-706-679-4749. Conference ID: 5661207.
Participants can access the live webcast through the following link:https://bit.ly/37N92wN
Consolidated Financial Statements and Management's Discussion and Analysis
The publication of InterCure's audited financial statements and accompanying notes for the year ended December 31, 2021 and related management's discussion and analysis of financial condition and results of operations ("MD&A") are available under the Company's profile on SEDAR.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its international market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Non-IFRS Measures
This press release makes reference to certain non-IFRS financial measures. Adjusted EBITDA, as defined by InterCure, means earnings before interest, income taxes, depreciation, and amortization, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses (or income). This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measured used by other entities or in other jurisdictions. InterCure uses this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the company. A reconciliation of Adjusted EBITDA to an IFRS measure (revenue) is provided below:
Adjusted EBITDA Reconciliation (consolidated base) | FOURTH QUARTER | FULL YEAR | |||||
Q4-20 | Q4-21 | 2020 | 2021 | ||||
Comprehensive income (loss) | 4,188 | (1,244) | (14,756) | 2,987 | |||
Interest / Financing cost | (94) | 2,659 | (38) | 3,870 | |||
Tax expenses (income) | (1,042) | 2,291 | (929) | 4,684 | |||
Depreciation and amortization | 438 | 1,314 | 1,332 | 3,027 | |||
EBITDA | 3,491 | 5,020 | (14,391) | 14,568 | |||
Share-based payment expenses | 686 | 479 | 4,098 | 2,641 | |||
Other expenses (income), net | 381 | 643 | 1,868 | 1,217 | |||
Impairment losses and (gains) on financial assets through profit and loss | (1,085) | 901 | 15,229 | 765 | |||
Fair value adjustment to inventory | (129) | 920 | (650) | 1,989 | |||
Adjusted EBITDA | 3,344 | 7,963 | 6,154 | 21,179 |
*All amounts shown in CAD
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to InterCure’s objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes”, “hopes”, “may”, “anticipates”, “should”, “intends”, “plans”, “will”, “expects”, “estimates”, “projects”, “positioned”, “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s future revenue growth and profitability, the success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic and the war in Ukraine. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. and Canadian regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under the heading “Risk Factors” in Subversive Acquisition LP’s final long form prospectus dated March 15, 2021, which is available on SEDAR at www.sedar.com, and under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form 20-F, filed with the Securities Exchange Commission on July 14, 2021, as amended August 3, 2021 and August 18, 2021. InterCure undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Contact:
InterCure Ltd.Amos Cohen, Chief Financial OfficerAmos@intercure.co
1 Year Intercure Chart |
1 Month Intercure Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions